Program
SHR-1139
A development code. Also written as “SHR-1139 Injection”, “SHR-1139 and SHR-1139 pleacebo” and “The SHR-1139 injection”.
In Jiangsu HengRui Medicine's pipeline, IL23p19/ IL36R
. Its studies are mostly in Psoriasis · Colitis, Ulcerative · Pyoderma Gangrenosum, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 87 open or running | phase 2since Mar 9, 2025 | Mar 9, 2025 | Dec 31, 2026phase 2 · NCT07719530 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-1139
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2025First study: phase 2 study in Moderate to Severe Plaque PsoriasisFirst studyNCT06875934 · 145 enrolled · China
- Jun 26, 2025Phase 1 study in Moderate to Severe Plaque PsoriasisNCT07051538 · 64 enrolled · China
- Jul 13, 2025Phase 1 study in PsoriasisNCT07078695 · 24 enrolled · Australia
- Nov 14, 2025Phase 2 study in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT07232576 · 21 enrolled · China
- Feb 26, 2026Phase 2 study in Pyoderma GangrenosumNCT07444684 · 20 planned · China
- Jul 17, 20262 phase 2 studiesNCT07719530, NCT07758075
- Oct 30, 2026Phase 2 study in Palmoplantar Pustulosis of AdultsNCT07923851 · 40 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in PsoriasisNCT07719530
- Jun 2027Primary completion: phase 2 study in Pyoderma GangrenosumNCT07444684
- Jul 2027Primary completion: phase 2 study in Plaque PsoriasisNCT07758075
- Aug 2027Primary completion: phase 2 study in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT07232576
TargetBeta
“IL23p19/ IL36R”the company's pipeline, read by Claude · source
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923851Palmoplantar Pustulosis of Adults · China | 2 | Not yet recruiting | Nov 2027 | 40 |
| NCT07758075Plaque Psoriasis · China | 2 | Not yet recruiting | Jul 2027 | 50 |
| NCT07719530Psoriasis · China | 2 | Recruiting | Dec 31, 2026 | 60 |
| NCT07444684Pyoderma Gangrenosum · China | 2 | Not yet recruiting | Jun 2027 | 20 |
| NCT07232576Adult Patients With Moderately to Severely Active Ulcerative Colitis · China | 2 | Active, not recruiting | Aug 2027 | 21 |
| NCT07078695Psoriasis · Australia | 1 | Active, not recruiting | Sep 30, 2026 | 24 |
| NCT07051538Moderate to Severe Plaque Psoriasis · China | 1 | Completed | Nov 28, 2025 | 64 |
| NCT06875934Moderate to Severe Plaque Psoriasis · China | 2 | Active, not recruiting | Nov 2025 | 145 |
How it is read
Names in the registry
- “SHR-1139 Injection”, 6 entries
- “SHR-1139 and SHR-1139 pleacebo”, 2 entries
- “The SHR-1139 injection”, 1 entry
- “SHR-1139”, 1 entry
- “SHR-1139 intravenous injection.”, 1 entry
Codes read as this program: SHR1139.
Conditions, from the studies’ own filings
- Psoriasis, 5 studies
- Colitis, Ulcerative, 1 study
- Pyoderma Gangrenosum, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.